400 related articles for article (PubMed ID: 23388639)
1. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.
Pang WW; Pluvinage JV; Price EA; Sridhar K; Arber DA; Greenberg PL; Schrier SL; Park CY; Weissman IL
Proc Natl Acad Sci U S A; 2013 Feb; 110(8):3011-6. PubMed ID: 23388639
[TBL] [Abstract][Full Text] [Related]
2. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
[TBL] [Abstract][Full Text] [Related]
3. Phagocytosis checkpoints on hematopoietic stem cells in patients with myelodysplastic syndromes.
Dong X; Han Y; Liu Y; Yang L; Niu H; Yan L; Liu C; Shao Z; Xing L; Wang H
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e119-e128. PubMed ID: 34152084
[TBL] [Abstract][Full Text] [Related]
4. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
5. Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.
Dimitriou M; Woll PS; Mortera-Blanco T; Karimi M; Wedge DC; Doolittle H; Douagi I; Papaemmanuil E; Jacobsen SE; Hellström-Lindberg E
Oncotarget; 2016 Nov; 7(45):72685-72698. PubMed ID: 27683035
[TBL] [Abstract][Full Text] [Related]
6. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
Asano H; Hotta T; Ichihara M; Murate T; Kobayashi M; Saito H
Leukemia; 1994 May; 8(5):833-8. PubMed ID: 7514249
[TBL] [Abstract][Full Text] [Related]
7. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.
Nilsson L; Astrand-Grundström I; Arvidsson I; Jacobsson B; Hellström-Lindberg E; Hast R; Jacobsen SE
Blood; 2000 Sep; 96(6):2012-21. PubMed ID: 10979941
[TBL] [Abstract][Full Text] [Related]
8. Proliferation and differentiation of myelodysplastic CD34+ cells: phenotypic subpopulations of marrow CD34+ cells.
Sawada K; Sato N; Notoya A; Tarumi T; Hirayama S; Takano H; Koizumi K; Yasukouchi T; Yamaguchi M; Koike T
Blood; 1995 Jan; 85(1):194-202. PubMed ID: 7528567
[TBL] [Abstract][Full Text] [Related]
9. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.
Nilsson L; Astrand-Grundström I; Anderson K; Arvidsson I; Hokland P; Bryder D; Kjeldsen L; Johansson B; Hellström-Lindberg E; Hast R; Jacobsen SE
Blood; 2002 Jul; 100(1):259-67. PubMed ID: 12070035
[TBL] [Abstract][Full Text] [Related]
10. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
[TBL] [Abstract][Full Text] [Related]
11. Stem cell concepts in myelodysplastic syndromes: lessons and challenges.
Woll PS; Jacobsen SEW
J Intern Med; 2021 May; 289(5):650-661. PubMed ID: 33843081
[TBL] [Abstract][Full Text] [Related]
12. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
[TBL] [Abstract][Full Text] [Related]
13. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.
Will B; Zhou L; Vogler TO; Ben-Neriah S; Schinke C; Tamari R; Yu Y; Bhagat TD; Bhattacharyya S; Barreyro L; Heuck C; Mo Y; Parekh S; McMahon C; Pellagatti A; Boultwood J; Montagna C; Silverman L; Maciejewski J; Greally JM; Ye BH; List AF; Steidl C; Steidl U; Verma A
Blood; 2012 Sep; 120(10):2076-86. PubMed ID: 22753872
[TBL] [Abstract][Full Text] [Related]
14. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
15. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
[TBL] [Abstract][Full Text] [Related]
17. Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro.
Bouscary D; Chen YL; Guesnu M; Picard F; Viguier F; Lacombe C; Dreyfus F; Fontenay-Roupie M
Exp Hematol; 2000 Jul; 28(7):784-91. PubMed ID: 10907640
[TBL] [Abstract][Full Text] [Related]
18. Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome.
Sato T; Kim S; Selleri C; Young NS; Maciejewski JP
Leukemia; 1998 Aug; 12(8):1187-94. PubMed ID: 9697872
[TBL] [Abstract][Full Text] [Related]
19. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
20. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.
Gupta P; Niehans GA; LeRoy SC; Gupta K; Morrison VA; Schultz C; Knapp DJ; Kratzke RA
Leukemia; 1999 Jan; 13(1):44-53. PubMed ID: 10049059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
